Mapi Pharma Presents New GA Depot Data at ACTRIMS Forum 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5d ago
0mins
Should l Buy VTRS?
Source: Newsfilter
- Clinical Trial Results: Mapi Pharma's presentation at the ACTRIMS Forum reveals that GA Depot's Phase II study in 30 PPMS patients resulted in an improvement in EDSS scores from 5.1 at baseline to 4.5 after three years, indicating significant efficacy in stabilizing disability, with 96.6% of patients showing no confirmed disability progression over 12 weeks, highlighting its therapeutic potential.
- Safety Assessment: The treatment with GA Depot was generally well tolerated, with 81.6% of adverse events being mild, primarily injection site reactions and asthenia, and the lower incidence of adverse events in the 25 mg group compared to the 40 mg group suggests that dose optimization may enhance patient experience.
- Market Outlook: Mapi Pharma has received GMP approval from the Israeli Ministry of Health, enabling the initiation of a Phase III study for GA Depot in 2026, with plans for a commercial launch targeting relapsing forms of multiple sclerosis (RMS) in 2027, which could significantly expand its market share.
- Strategic Partnership: Mapi has entered into an exclusive global licensing agreement with Viatris to co-develop GA Depot for RMS, further solidifying its market position in the biopharmaceutical sector and laying a strong foundation for future collaborative development efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTRS
Wall Street analysts forecast VTRS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTRS is 13.25 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
2 Buy
1 Hold
1 Sell
Hold
Current: 14.340
Low
10.00
Averages
13.25
High
16.00
Current: 14.340
Low
10.00
Averages
13.25
High
16.00
About VTRS
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viatris Announces Q4 and Full Year 2025 Financial Results Release
- Earnings Release Schedule: Viatris plans to report its Q4 and full year 2025 financial results on February 26, 2026, with executives hosting a webcast at 8:30 a.m. ET to discuss performance details with investors and the public.
- Investor Event Announcement: The company will hold an Investor Event in New York City on March 19, 2026, with more details to be provided during the February investor call, aiming to enhance engagement with analysts and institutional investors.
- Webcast Access: Investors can participate in the earnings call via the company’s website or by calling designated numbers, with a replay available online, ensuring that those unable to attend live can still access the information.
- Global Healthcare Mission: Viatris is committed to providing high-quality healthcare to approximately 1 billion patients worldwide through its extensive portfolio and global supply chain, highlighting the company's unique position and mission in the global health sector.
See More
Viatris Announces Q4 and Full Year 2025 Financial Results Release
- Earnings Release Schedule: Viatris plans to report its Q4 and full year 2025 financial results on February 26, 2026, with executives hosting a webcast at 8:30 a.m. ET to enhance transparency and communication with investors and the public.
- Investor Event Announcement: The company will hold an Investor Event in New York City on March 19, 2026, providing further details during the February investor call, aimed at strengthening interactions with analysts and institutional investors to enhance investor relations management.
- Webcast Access: Investors can participate in the earnings call and investor event via the company’s website or designated phone lines, ensuring broad participation and providing replay services to further expand information dissemination.
- Global Healthcare Mission: Viatris is committed to providing high-quality healthcare services to approximately 1 billion patients worldwide through its diverse portfolio of medicines, reflecting the company's unique positioning and strategic significance in addressing health needs at various life stages.
See More
Mapi Pharma Presents New GA Depot Data at ACTRIMS Forum 2026
- Clinical Trial Results: Mapi Pharma's presentation at the ACTRIMS Forum reveals that GA Depot's Phase II study in 30 PPMS patients resulted in an improvement in EDSS scores from 5.1 at baseline to 4.5 after three years, indicating significant efficacy in stabilizing disability, with 96.6% of patients showing no confirmed disability progression over 12 weeks, highlighting its therapeutic potential.
- Safety Assessment: The treatment with GA Depot was generally well tolerated, with 81.6% of adverse events being mild, primarily injection site reactions and asthenia, and the lower incidence of adverse events in the 25 mg group compared to the 40 mg group suggests that dose optimization may enhance patient experience.
- Market Outlook: Mapi Pharma has received GMP approval from the Israeli Ministry of Health, enabling the initiation of a Phase III study for GA Depot in 2026, with plans for a commercial launch targeting relapsing forms of multiple sclerosis (RMS) in 2027, which could significantly expand its market share.
- Strategic Partnership: Mapi has entered into an exclusive global licensing agreement with Viatris to co-develop GA Depot for RMS, further solidifying its market position in the biopharmaceutical sector and laying a strong foundation for future collaborative development efforts.
See More
Viatris Appoints New Chief Legal Officer Following Brian Roman's Departure
- Executive Transition: Viatris announced the appointment of Matthew J. Maletta as the new Chief Legal Officer, succeeding Brian Roman, who has served for over 20 years and will remain as an advisor during the transition period to ensure smooth legal operations.
- Extensive Experience: Maletta brings nearly 30 years of legal expertise in the pharmaceutical industry, having previously served as Chief Legal Officer at Endo, where he oversaw the merger with Mallinckrodt and the subsequent spin-off, showcasing his capability in managing complex transactions.
- Leadership Acknowledgment: Viatris CEO Scott A. Smith expressed gratitude for Roman's contributions, highlighting his legal expertise's critical role in the company's development, while also expressing excitement for Maletta's addition, believing it will strengthen the company's legal and compliance team.
- Company Vision: Maletta stated that joining Viatris represents a unique opportunity, looking forward to building the future with the team and further driving the company's transformation and long-term growth, reflecting the company's mission in the global healthcare sector.
See More
Viatris (VTRS) Launches Inpefa in UAE, Plans Future Expansions Across Multiple Countries
- Drug Launch: Viatris has launched Inpefa (sotagliflozin) in the UAE, marking the first commercialization of this heart failure treatment within its territories and initiating its global expansion strategy.
- Clinical Trial Results: Inpefa demonstrated a 33% reduction in the composite risk of heart failure hospitalization, urgent visits, and cardiovascular death in recently hospitalized patients, based on over 11,800 participants in two pivotal Phase 3 trials.
- Cardiovascular Risk Reduction: In the SCORED trial, Inpefa achieved a 25% reduction in the same composite endpoint among patients with type 2 diabetes and chronic kidney disease, highlighting its significance in cardiovascular disease management.
- Market Reaction: Despite VTRS shares trading at $12.73, down 1.01% in pre-market activity, the drug's launch is expected to drive future revenue growth and enhance market share for the company.
See More
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
- Leadership Change: Viatris has appointed Lara Ramsburg as Chief People and Corporate Affairs Officer, aiming to enhance company culture and global connectivity through integrated internal and external communication strategies, which will improve employee engagement and corporate image.
- Experienced Leader: With over 25 years of experience leading cross-functional teams, Ramsburg's previous roles at Viatris and its legacy company Mylan, particularly in corporate affairs, will help maintain strategic alignment during the company's transformation.
- Strategic Integration: In her new role, Ramsburg will oversee critical areas such as global talent, employee experience, and HR solutions, enhancing the company's strategic execution in employee welfare and development.
- Future Outlook: Viatris executive Andrew Enrietti stated that Ramsburg's appointment will support the company as it enters its next growth phase, emphasizing that employee engagement and well-being are the company's most important assets, which will continue to drive the achievement of strategic objectives.
See More
Viatris Announces Q4 and Full Year 2025 Financial Results Release
- Earnings Release Schedule: Viatris plans to report its Q4 and full year 2025 financial results on February 26, 2026, with executives hosting a webcast at 8:30 a.m. ET to discuss performance details with investors and the public.
- Investor Event Announcement: The company will hold an Investor Event in New York City on March 19, 2026, with more details to be provided during the February investor call, aiming to enhance engagement with analysts and institutional investors.
- Webcast Access: Investors can participate in the earnings call via the company’s website or by calling designated numbers, with a replay available online, ensuring that those unable to attend live can still access the information.
- Global Healthcare Mission: Viatris is committed to providing high-quality healthcare to approximately 1 billion patients worldwide through its extensive portfolio and global supply chain, highlighting the company's unique position and mission in the global health sector.
See More
Viatris Announces Q4 and Full Year 2025 Financial Results Release
- Earnings Release Schedule: Viatris plans to report its Q4 and full year 2025 financial results on February 26, 2026, with executives hosting a webcast at 8:30 a.m. ET to enhance transparency and communication with investors and the public.
- Investor Event Announcement: The company will hold an Investor Event in New York City on March 19, 2026, providing further details during the February investor call, aimed at strengthening interactions with analysts and institutional investors to enhance investor relations management.
- Webcast Access: Investors can participate in the earnings call and investor event via the company’s website or designated phone lines, ensuring broad participation and providing replay services to further expand information dissemination.
- Global Healthcare Mission: Viatris is committed to providing high-quality healthcare services to approximately 1 billion patients worldwide through its diverse portfolio of medicines, reflecting the company's unique positioning and strategic significance in addressing health needs at various life stages.
See More
Mapi Pharma Presents New GA Depot Data at ACTRIMS Forum 2026
- Clinical Trial Results: Mapi Pharma's presentation at the ACTRIMS Forum reveals that GA Depot's Phase II study in 30 PPMS patients resulted in an improvement in EDSS scores from 5.1 at baseline to 4.5 after three years, indicating significant efficacy in stabilizing disability, with 96.6% of patients showing no confirmed disability progression over 12 weeks, highlighting its therapeutic potential.
- Safety Assessment: The treatment with GA Depot was generally well tolerated, with 81.6% of adverse events being mild, primarily injection site reactions and asthenia, and the lower incidence of adverse events in the 25 mg group compared to the 40 mg group suggests that dose optimization may enhance patient experience.
- Market Outlook: Mapi Pharma has received GMP approval from the Israeli Ministry of Health, enabling the initiation of a Phase III study for GA Depot in 2026, with plans for a commercial launch targeting relapsing forms of multiple sclerosis (RMS) in 2027, which could significantly expand its market share.
- Strategic Partnership: Mapi has entered into an exclusive global licensing agreement with Viatris to co-develop GA Depot for RMS, further solidifying its market position in the biopharmaceutical sector and laying a strong foundation for future collaborative development efforts.
See More
Viatris Appoints New Chief Legal Officer Following Brian Roman's Departure
- Executive Transition: Viatris announced the appointment of Matthew J. Maletta as the new Chief Legal Officer, succeeding Brian Roman, who has served for over 20 years and will remain as an advisor during the transition period to ensure smooth legal operations.
- Extensive Experience: Maletta brings nearly 30 years of legal expertise in the pharmaceutical industry, having previously served as Chief Legal Officer at Endo, where he oversaw the merger with Mallinckrodt and the subsequent spin-off, showcasing his capability in managing complex transactions.
- Leadership Acknowledgment: Viatris CEO Scott A. Smith expressed gratitude for Roman's contributions, highlighting his legal expertise's critical role in the company's development, while also expressing excitement for Maletta's addition, believing it will strengthen the company's legal and compliance team.
- Company Vision: Maletta stated that joining Viatris represents a unique opportunity, looking forward to building the future with the team and further driving the company's transformation and long-term growth, reflecting the company's mission in the global healthcare sector.
See More
Viatris (VTRS) Launches Inpefa in UAE, Plans Future Expansions Across Multiple Countries
- Drug Launch: Viatris has launched Inpefa (sotagliflozin) in the UAE, marking the first commercialization of this heart failure treatment within its territories and initiating its global expansion strategy.
- Clinical Trial Results: Inpefa demonstrated a 33% reduction in the composite risk of heart failure hospitalization, urgent visits, and cardiovascular death in recently hospitalized patients, based on over 11,800 participants in two pivotal Phase 3 trials.
- Cardiovascular Risk Reduction: In the SCORED trial, Inpefa achieved a 25% reduction in the same composite endpoint among patients with type 2 diabetes and chronic kidney disease, highlighting its significance in cardiovascular disease management.
- Market Reaction: Despite VTRS shares trading at $12.73, down 1.01% in pre-market activity, the drug's launch is expected to drive future revenue growth and enhance market share for the company.
See More
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
- Leadership Change: Viatris has appointed Lara Ramsburg as Chief People and Corporate Affairs Officer, aiming to enhance company culture and global connectivity through integrated internal and external communication strategies, which will improve employee engagement and corporate image.
- Experienced Leader: With over 25 years of experience leading cross-functional teams, Ramsburg's previous roles at Viatris and its legacy company Mylan, particularly in corporate affairs, will help maintain strategic alignment during the company's transformation.
- Strategic Integration: In her new role, Ramsburg will oversee critical areas such as global talent, employee experience, and HR solutions, enhancing the company's strategic execution in employee welfare and development.
- Future Outlook: Viatris executive Andrew Enrietti stated that Ramsburg's appointment will support the company as it enters its next growth phase, emphasizing that employee engagement and well-being are the company's most important assets, which will continue to drive the achievement of strategic objectives.
See More
